Italia markets closed

Arbutus Biopharma Corporation (ABUS)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
2,2800-0,1200 (-5,00%)
Alla chiusura: 04:00PM EDT
2,2815 +0,00 (+0,07%)
Dopo ore: 04:20PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente2,4000
Aperto2,3600
Denaro2,2800 x 2200
Lettera2,3400 x 3000
Min-Max giorno2,2800 - 2,3900
Intervallo di 52 settimane1,9300 - 6,5000
Volume611.065
Media Volume929.967
Capitalizzazione341,888M
Beta (5 anni mensile)2,24
Rapporto PE (ttm)N/D
EPS (ttm)-0,7050
Prossima data utili02 nov 2022 - 07 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A6,30
  • GlobeNewswire

    Arbutus Reports Second Quarter 2022 Financial Results and Provides Corporate Update

    Key milestones across our chronic hepatitis B virus (cHBV) and pan-coronavirus programs remain on track Financially strong with a projected cash runway into the second quarter of 2024 Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reports its

  • GlobeNewswire

    Arbutus to Report Second Quarter 2022 Financial Results and Provide Corporate Update

    WARMINSTER, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its second quarter 2022 financial results and corporate update for Thursday, August 4, 2022. The schedule for the press release and conference call/webcast are as follows: •Q2/2022 Press Release:Thursday, August

  • GlobeNewswire

    Arbutus Biopharma Provides Update on the Phase 2A Combination Trial with AB-729 and a Capsid Inhibitor

    Triple combination clinical trial evaluating AB-729, an RNAi therapeutic, vebicorvir, Assembly Biosciences’ core inhibitor, and nucleos(t)ide analog continues with data expected in 2H 2022 WARMINSTER, Pa., July 20, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that while its partner, Assembly Biosciences